Rationale: Rifabutin was recommended in place of rifampin during treatment of HIV-related tuberculosis (TB) to facilitate concomitant potent antiretroviral therapy, but this approach has not been evaluated in a prospective study. Objective: To evaluate the activity of intermittent rifabutin-based therapy. Methods: Patients with culture-confirmed TB were treated under direct supervision with 2 mo of rifabutin, isoniazid, pyrazinamide, and ethambutol (given daily, thrice-weekly, or twice-weekly per the local tuberculosis control program), followed by 4 mo of twiceweekly rifabutin plus isoniazid. Measurements: Culture-positive treatment failure or relapse. Main Results: A total of 169 eligible patients were enrolled. Most had advanced HIV disease; the median CD4 cell count and HIV-RNA level were 90 cells/mm 3 (interquartile range, 35-175) and 5.3 log 10 copies/ml (interquartile range, 4.8-5.7), respectively. Nine (5.3%) patients had culture-positive treatment failure (n ϭ 3) or relapse (n ϭ 6). Eight of these nine (89%) cases had isolates with acquired rifamycin resistance. Treatment failure or relapse was associated with baseline CD4 lymphocyte count, being 12.3% (9/73; 95% confidence interval, 6.5-22.0%) among patients with CD4 Ͻ 100 cells/mm 3 versus 0% (0/65; 95% confidence interval, 0.0-4.5%) among those with higher CD4 lymphocyte counts (p Ͻ 0.01). One hundred thirty-seven (81%) patients received antiretroviral therapy during TB treatment. Adverse events were common, but only two patients (1%) permanently discontinued study drugs. Conclusions: Intermittent rifabutin-based therapy for HIV-related TB was well tolerated, but there was a high risk of treatment failure or relapse with acquired rifamycin resistance among patients with low CD4 lymphocyte counts.
complications of HIV (4, 5) . Antiretroviral therapy markedly improves survival among patients with advanced HIV disease (7, 8) and may improve survival with HIV-related TB (9) . However, the use of combination antiretroviral therapy during treatment of TB is complicated by overlapping side-effect profiles of anti-TB and antiretroviral drugs, complex drug-drug interactions between the rifamycins and many antiretroviral drugs, and immune reconstitution reactions after initiation of antiretroviral therapy (10) .
Rifampin markedly decreases serum concentrations of the HIV-1 protease inhibitors (11) , and has substantial effects on concentrations of two of the available nonnucleoside reversetranscriptase inhibitors (delavirdine and nevirapine) (12) , thus limiting the choice of antiretroviral drugs. An alternate rifamycin antibiotic, rifabutin, has much less effect on serum concentrations of these antiretroviral drugs (12) and appears to be as potent as rifampin for the treatment of TB (13) (14) (15) . Therefore, rifabutin-based therapy was recommended by the Centers for Disease Control and Prevention (CDC) as a way of avoiding serious drug-drug interactions and allowing use of potent antiretroviral therapy during TB treatment (16) . However, there is relatively little published clinical experience with rifabutin-based therapy for HIV-related TB (15) . The Tuberculosis Trials Consortium evaluated the efficacy and tolerability of a standard rifabutin-based regimen for treatment of HIV-related TB (TBTC Study 23) . Preliminary results of this study were reported in the form of an abstract (17) and a special "Note to Readers" of the Morbidity and Mortality Weekly Report (18) .
METHODS
Patients 18 yr or older at participating sites in the United States and Canada with confirmed HIV infection and suspected or confirmed TB were eligible for enrollment. Patients were excluded if they had received treatment for active or latent TB within the previous 6 mo, were pregnant or breast-feeding, or if the initial mycobacterial cultures were negative or grew rifamycin-resistant Mycobacterium tuberculosis. The study was reviewed and approved by the institutional review boards of the CDC and each clinical site. All patients gave written, informed consent.
Patients could be enrolled at any time during the first 2 mo of TB treatment. Patients who enrolled before the completion of the intensive phase of therapy (the first 2 mo) received rifabutin, isoniazid, pyrazinamide, and ethambutol, given daily for the first 2 wk and then either daily (5 d/wk), thrice-weekly, or twice-weekly based on the preference of the local TB control program. After 2 mo, all patients were treated with rifabutin (300 mg) plus isoniazid (15 mg/kg; maximum, 900 mg) given twice weekly. All TB treatment was given as directly observed therapy, defined as the ingestion of study medication under the observation of a member of the study team. Completion of study therapy was defined as observed ingestion of 36 twice-weekly continuation-phase doses, not by calendar time. The type and timing of initiation of antiretroviral therapy were not determined by the study protocol. Rifabutin doses were adjusted according to current guidelines if given with the HIV-1 protease inhibitors or efavirenz (19) .
TB treatment duration was 6 mo, with a mandatory extension to 9 mo for patients with a positive culture or lack of a clinical response at 2 mo of treatment (defined as persistent fever or progressive weight loss, and increase in size of lymph nodes, abscesses, or other tuberculous lesions) (16) . Patients having an isoniazid-resistant isolate or who were intolerant of isoniazid were treated with 9 mo of rifabutin, pyrazinamide, and ethambutol; those having a pyrazinamide-resistant isolate or who were intolerant of pyrazinamide were treated with 9 mo of rifabutin plus isoniazid.
CD4 lymphocyte count and HIV-RNA level (bDNA Bayer Versant 3.0; Bayer Corporation, Tarrytown, NY) were performed at enrollment, after 2 mo of TB therapy, at end of treatment, and every 6 mo thereafter. We attempted to obtain sputum specimens from all patients at 2 mo of treatment, regardless of the presence or absence of clinically evident pulmonary involvement. Patients with pulmonary involvement had sputum cultures obtained monthly during therapy and then at 1.5, 3, 6, 12, 18, and 24 mo after completing therapy. At all of these time points, patients who could not produce an expectorated sputum specimen underwent sputum induction. Mycobacterial cultures were performed using liquid plus solid media at certified local laboratories. Isolates obtained at diagnosis and at the time of treatment failure or relapse underwent confirmatory drug-susceptibility testing (using solid media and the proportion method), DNA fingerprinting (20, 21) , and sequencing of the rpoB gene (22) .
The primary endpoint of the study was culture-confirmed treatment failure (positive culture during treatment, at or after Month 4) or relapse (positive culture after completing treatment). The planned sample size was 215 patients, allowing for 80% power to detect whether the rate of treatment failure plus relapse was higher than 10%, twice that expected for treatment of drug-susceptible TB (р 5%).
Data Analysis
All patients with culture-positive TB are included in the primary analysis; a second analysis was performed using patients who completed therapy as specified in the protocol. Categoric variables were compared using the two-tailed Fisher's exact test or 2 , and continuous variables with the Wilcoxon two-sample test. To identify factors associated with acquired rifamycin resistance, we compared patients having acquired rifamycin resistance to all other patients in the study. All patients in the study completed 8 wk of four-drug therapy, but there were differences in the amount of that therapy that was administered twice-weekly. For the analysis of risk factors for acquired rifamycin resistance, patients who received four or more doses of their treatment as twice-weekly dosing during the first 2 mo were defined as having received twiceweekly therapy during induction phase. Because of the small number of cases of treatment failure or relapse it was not appropriate to perform multivariate analysis (23) . However, among the 73 patients with a baseline CD4 cell count below 100 (which included all eight patients with acquired rifamycin resistance), we performed a stratified analysis of those factors associated with acquired rifamycin resistance in univariate analysis (p Ͻ 0.20). Data analysis was performed using SAS version 8.0 (SAS Institute, Cary, NC) and EpiInfo, version 6.04d (CDC, Atlanta, GA).
RESULTS
A total of 180 patients were enrolled between December 1998 and March 2002 (Figure 1 ), 11 of whom were later excluded from the study (eight patients who did not have a positive mycobacterial culture and three patients who enrolled at sites that were closed soon after study initiation). The 169 remaining patients were used for the analyses that follow. Most patients were male and of Black or Hispanic race/ethnicity; 40% were born outside of the United States and Canada (Table 1) . Nearly 45% of patients had extrapulmonary manifestations of TB; 22 (13%) had only extrapulmonary involvement. Most patients had advanced HIV disease at the time of TB diagnosis; the median CD4 cell count and HIV-RNA level were 90 cells/mm 3 (interquartile range, 35-175) and 5.3 log 10 copies/ml (interquartile range, 4.8-5.7), respectively. A data and safety monitoring board reviewed outcome data three times. In March 2002, the board recommended that enrollment be stopped because five cases of acquired rifamycin resistance had occurred among patients with treatment failure or relapse. At the time enrollment was stopped, investigators were encouraged to use more frequent therapy (daily or thrice-weekly) and/or add medications such as ethambutol for patients having CD4 lymphocyte counts of less than 100 cells/mm 3 at study entry. Patients were monitored for 2 yr after completing therapy.
TB Treatment
Of the 169 patients, 37 (22%) enrolled before starting TB treatment, and were therefore treated with rifabutin from the outset. The other 132 patients were enrolled during the first 2 mo of therapy and had received a median of 33.5 d of rifampincontaining therapy (interquartile range, 16.5-56 d). During the first 2 mo of TB treatment, 76 (45%) of patients received twiceweekly therapy. Most patients were treated for 6 mo. Treatment was extended to 9 mo for 16 patients (eight patients who were intolerant to or had an isolate resistant to isoniazid [n ϭ 5] or pyrazinamide [n ϭ 3], four patients who had a positive sputum culture at 2 mo of treatment, two patients with lack of clinical response by 2 mo, and two patients because of provider preference). Thirty of 169 (17.8%) were lost to follow-up before completing the study or reaching an endpoint (Figure 1) . However, the lost-to-follow-up rate at 12 mo after completing therapy, the period of highest risk for recurrent TB, was 7.1% (12 of 169).
Treatment Failure and Relapse
Nine patients had culture-positive treatment failure or relapse: three patients had treatment failure and six had relapse. Four of the six cases of relapse occurred within 6 mo of completing TB treatment. Overall, 5.3% (9 of 169) of patients had treatment failure or relapse; by Kaplan-Meier analysis, 6.6% of patients had treatment failure or relapse by 2 yr after completing therapy. The rate of treatment failure or relapse was 3.0 per 100 patientyears of follow-up. Among the 142 patients who completed the study regimen as specified in the protocol, eight (5.6%) had treatment failure or relapse (one patient with acquired rifamycin resistance had treatment failure after nonadherence). Treatment failure or relapse was associated with baseline CD4 lymphocyte count, being 12.3% (9/73; 95% confidence interval, 6.5-22.0%) among patients with CD4 counts of less than 100 cells/mm 3 versus 0% (0/65; 95% confidence interval, 0.0-4.5%) among those with higher CD4 lymphocyte counts (p Ͻ 0.01).
Eight of the nine isolates (89%) obtained at the time of treatment failure or relapse had acquired rifamycin resistance (three cases of treatment failure and five cases of relapse). The median time from enrollment to acquired rifamycin resistance was 8.3 mo (range, 4.7-24.5 mo). Multidrug resistance developed in one of these cases. A patient with an isolate having baseline pyrazinamide resistance developed recurrent suppurative cervical adenopathy at 5 mo of directly observed therapy. A percutaneous aspirate yielded an isolate with acquired rifamycin and isoniazid resistance. For all nine cases, the DNA fingerprint patterns of paired isolates at initial diagnosis and the time of treatment failure or relapse were identical. The rpoB gene sequences of the eight isolates having acquired rifamycin resistance had mutations previously associated with rifampin resistance (Ser531Leu [three cases], Gln513Leu [two cases], His526Tyr [two cases], His526Asp [one case]) (22) . All patients with treatment failure or relapse responded to retreatment with a regimen active against rifamycin-resistant TB.
Factors Associated with Rifamycin-resistant Treatment Failure or Relapse
Patients with acquired rifamycin treatment failure or relapse had lower CD4 lymphocyte counts at the time of TB diagnosis than other patients (median CD4
Canada, the presence of extrapulmonary manifestations of TB, twice-weekly TB treatment during the first 2 mo of TB treatment, and lack of use of antiretroviral therapy during the first 2 mo of TB treatment were more common among cases with acquired rifamycin resistance ( Table 2) . Use of rifampin during intensive-phase therapy was not associated with risk of acquired rifamycin resistance. In a stratified analysis of those patients with baseline CD4 lymphocyte count of less than 100 cells/mm 3 , lack of use of antiretroviral therapy during the first 2 mo of TB treatment remained of borderline statistical significance (Table 3 ; p Ͻ 0.07).
Use of Antiretroviral Therapy
Thirty-eight (22%) patients were on antiretroviral therapy at the time of TB diagnosis, and 99 patients (59%) started antiretroviral therapy during TB treatment. Therefore, 81% of patients (137 of 169) received antiretroviral therapy during TB treatment.
Patients not started on antiretroviral therapy during TB treatment had higher CD4 lymphocyte counts than those who received antiretroviral therapy during TB treatment (median CD4 lymphocyte count among those who did not start antiretroviral therapy, 149 cells/mm 3 [interquartile range, 73-261] vs. 79 [interquartile range, 32-150]; p ϭ 0.02). All patients who were treated with antiretroviral treatment received combination therapy; the most common regimens were two nucleoside analogs plus nelfinavir (47 patients) and two nucleoside analogs plus efavirenz (45 patients). CD4 lymphocyte counts rose substantially and HIV-RNA levels decreased during TB treatment (Figure 2 ). Twenty-six of the 169 patients (15%) were diagnosed with immune reconstitution reactions, all of which occurred among patients receiving antiretroviral therapy (26 of 137, 19%).
Adverse Events
Of 169 patients in the study, 25 (14.8%) died and 25 (14.8%) developed a new AIDS-defining condition (24) . None of the deaths were due to TB; 17 were due to complications of HIV disease (AIDS wasting, five patients; opportunistic infection, nine patients; HIV-related malignancy, three patients), three to illicit drug overdose, and five to other causes (suicide, cardiovascular disease, liver failure, non-HIV-related cancer). Although adverse events were common during TB treatment, few were believed to be due to the TB treatment regimen, and only two patients permanently stopped study drugs due to an adverse event (Table 4) .
DISCUSSION
This study is the largest prospective evaluation of a rifabutinbased TB treatment regimen in conjunction with use of potent antiretroviral therapy. The rate of treatment failure or relapse observed in the study was approximately 5%, similar to that seen with standard rifampin-based TB therapy (5, 25), demonstrating the potency of rifabutin-based treatment for the treatment of HIV-related TB. The treatment regimen was also well tolerated, with only 1% of patients permanently discontinuing rifabutin due to an adverse event. However, eight of the nine patients who had treatment failure or relapse had isolates with acquired rifamycin resistance. Because rifamycins are the key to short-course TB treatment, the occurrence of acquired rifamycin resistance led to the early discontinuation of the study.
One of the most important benefits of directly observed therapy for TB is that it prevents selective drug taking, and thereby almost completely prevents acquired drug resistance (14, 26, 27) . However, this study demonstrates that this axiom of TB treatment is not true for patients with advanced HIV disease. It is also notable that the drug to which resistance was acquired in this and other studies (5, 25, 28, 29) was nearly always the rifamycin component of the regimen (rifampin, rifabutin, or rifapentine). Among patients with HIV-related TB treated with directly observed therapy, there are two consistent associations in this and previous studies with the occurrence of acquired rifamycin resistance: the presence of severe immunodeficiency (CD4 lymphocyte count Ͻ 100 cells/mm 3 ) and the use of onceor twice-weekly therapy. Acquired rifamycin resistance has been reported with twice-weekly rifabutin plus isoniazid (4.7% in the present study) and with twice-weekly rifampin plus isoniazid (2.0, 3.7, and 1.7%) (5, 29, 30) . In contrast, the rate of acquired rifamycin resistance among HIV-infected patients treated with daily (5-7 d/wk) rifampin-based therapy (29, 31, 32) , or rifabutinbased therapy (29, 31) has been very low. The interpretation of these data from different clinical trials and observational cohorts is difficult. We conclude that there is a risk of acquired rifamycin resistance with rifabutin or rifampin when given twice weekly, but whether the risk is higher with one of these agents is not clear. In addition to the associations with severity of immunosuppression and dosing frequency, abnormal pharmacokinetics of anti-TB drugs may also be a part of the pathophysiology of acquired rifamycin resistance. Among patients in this trial who enrolled in a pharmacokinetic substudy, patients with low concentrations of rifabutin were at increased risk of acquired rifamycin resistance, even after adjusting for baseline CD4 cell count and dosing frequency (33) . Thus, it appears that three factors are closely associated with acquired rifamycin resistance: severe immunodeficiency, highly intermittent dosing, and low concentrations of the rifamycin component of the regimen. These associations suggest that, in the relative absence of immune control, low concentrations of the rifamycin near the end of the prolonged dosing interval allow mycobacterial replication and selection for rifamycin resistance.
The risk of acquired rifamycin resistance in our study was lower among patients who received antiretroviral therapy during the first 2 mo of TB treatment. The interpretation of this finding is difficult: the study could not capture the many factors that led to differences in the timing of antiretroviral therapy, and this association has not been evaluated in previous studies. Although our sample size is relatively small, these data support the hypothesis that immune reconstitution is beneficial in the treatment of HIV-associated TB. The question of the optimal timing of antiretroviral therapy during TB treatment is complex and is currently being evaluated in randomized clinical trials.
The TB treatment regimen in this study was chosen to determine if TB treatment could be used safely with potent antiretroviral therapy. In that respect, the study regimen succeeded; most patients received and benefited from potent antiretroviral therapy during TB therapy. Baseline characteristics of patients in this trial were quite similar to those of patients enrolled in a trial that was performed in many of the same study sites, before the availability of potent antiretroviral therapy ( Table 5) . The markedly lower rates of death (4.9 vs. 20.0%) and new opportunistic illness during the first year after TB diagnosis in the present study suggest that the benefits of antiretroviral therapy can be extended to patients being treated for TB. This is an important finding because TB is the most common opportunistic infection in areas of the world with high rates of HIV infection, areas in which combination antiretroviral therapy is now being introduced. Rifabutin has only been approved in a relatively small number of resource-rich countries (e.g., United States and western Europe). This limits the direct application of our results to many countries with high rates of HIV-related TB in which rifampin is the only available rifamycin antibiotic. However, some potent antiretroviral regimens (e.g., efavirenz or ritonavir with two nucleoside analogs) can be used with rifampin-based TB therapy (11, 34) , and should allow patients to obtain the benefits of potent antiretroviral therapy given during TB treatment.
The major limitation of this study is the lack of a randomized comparison group. Although use of twice-weekly therapy was associated with acquired rifamycin resistance among patients with low baseline CD4 lymphocyte counts, our study did not include a group randomized to more frequent dosing. Evaluating the relationship between dosing frequency and the success of treatment of HIV-related TB should be a high priority for future randomized studies. Although this is one of the largest prospective studies of treatment of HIV-related TB, the sample size limits the power of subgroup comparisons. Finally, the substantial proportion of patients lost after the first year of follow-up, but before completing 2 yr of follow-up, is a limitation of our study.
A largely twice-weekly rifabutin-based regimen for HIVrelated TB was associated with an unacceptable risk of acquired rifamycin resistance. The results of this and other studies were the basis for national recommendations that persons with CD4 lymphocyte counts of less than 100 cells/mm 3 should not be treated with twice-weekly therapy, at least during the first 2 mo of therapy (18, 35) . Patients with baseline CD4 lymphocyte counts more than 100 cells/mm 3 did well in this study, but additional experience is needed to evaluate intermittent therapy in this important subgroup. Intermittent therapy greatly facilitates directly observed therapy, so randomized trials of dosing frequency should be a high priority among patients with HIVrelated TB. Finally, our study supports the recommendation to use antiretroviral therapy among patients with advanced HIV disease and TB (16) , as such patients can obtain dramatic benefits from potent antiretroviral therapy.
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